SecBot SecBot
Insider Cluster (2 insiders) ·Filed Aug 21, 2026

FDMT

4D Molecular Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed2mo ago
Insider cluster: 2 insiders, $683K total
Actionable Insight • Neutral

This insider cluster is routine option exercise-and-sell activity with no informational content. Monitor for any upcoming clinical data readouts or financing events as the primary catalysts for FDMT, not insider trading patterns.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d
FDMT ▲ +3.18% at T+20d
NEUTRAL call +3.18% · α vs SPY +1.89% · entry $15.39 → $15.88
Next anchor: T+60d in 20d
Latest observation: T+43 -48.49% FF3 residual α
Entry = T+0 close
Aug 21, 2026
via day close
T+1d
+2.14%
call +2.14% · α +1.82%
$15.72
settled 2mo ago
T+5d
-8.32%
call -8.32% · α -8.79%
$14.11
settled 2mo ago
T+20d
+3.18%
call +3.18% · α +1.89%
$15.88
settled 5w ago
T+60d
Pending
in 20d

Price Chart

Loading chart...

Executive Summary

CEO David Kirn and CLO Scott Bizily sold a combined ~$683K in open-market sales after exercising stock options. The CEO's sales ($663K) represent 0.08% of FDMT's $889M market cap, falling below the 0.1% materiality threshold. These are routine cashless exercises for tax obligations, not a bearish signal. The cluster is neutral — no material directional insight for traders.

Key Financial Metrics

Direction
selling
Total Value
$683.0K
Insiders
2

Key Facts

  • CEO David Kirn sold 43,149 shares at $15.36 for $663K on 2026-08-19 after exercising options at $4.14/share.
  • CLO Scott Bizily sold 1,635 shares at $12.20 for $20K on 2026-08-17 after exercising options.
  • Total open-market sales of ~$683K represent ~0.08% of FDMT's $889M market cap — below the 0.1% materiality threshold.
  • All sales were preceded by same-day option exercises, indicating routine cashless exercise-for-tax-covering transactions.
  • No 10b5-1 plan pattern detected, but the structure (exercise + immediate sale) is standard for option monetization.

Financial Impact

Total insider sales of ~$683K, or ~0.08% of market cap — immaterial relative to company size.

dilution

Risk Factors

  • Insider sales could accelerate if stock price rises further, but current volume is immaterial.
  • No bearish signal from this cluster — the risk is over-interpreting routine cashless exercises.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
83% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-FDMT-1787379152140
9 reports for FDMT
Performance horizon
100% Hit rate @ T+1 4 of 4 directional calls Went positive at some point 4 of 4 best @ T+20▲ +31.15%Jul 18, 2026
Filters
Rows
Reports for FDMT — sortable, filterable
TypeNow
Sep 22, 2026
4w ago
Insider Cluster
BEARISH ★ 4/10
$15.00 $14.71▲ +1.93%▲ +1.85%$10.80 (+28.00%)
Aug 21, 2026
9w ago
Insider Cluster
NEUTRAL ★ 3/10
$15.39 $15.72▲ +2.14%▲ +1.82%$10.80 (−29.82%)
Jul 20, 2026
14w ago
8-K
BULLISH ★ 7/10
$11.09 $11.38▲ +2.57%▲ +1.74%$10.80 (−2.61%)
Jul 18, 2026
14w ago
Press Release
BULLISH ★ 6/10
$11.09 $11.38▲ +2.57%▲ +1.74%$10.80 (−2.61%)
Jul 5, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 3/10
$12.72 $12.82▲ +0.79%▲ +1.26%$10.80 (−15.09%)
Jun 29, 2026
17w ago
8-K
BULLISH ★ 6/10
$12.88 $13.30▲ +3.26%▲ +2.48%$10.80 (−16.15%)
May 14, 2026
23w ago
EFFECT
NEUTRAL ★ 4/10
$9.81 $9.15▼ −6.73%▼ −5.50%$10.80 (+10.09%)
May 7, 2026
24w ago
S-3
NEUTRAL ★ 4/10
$10.14 $10.79▲ +6.41%▲ +6.18%$10.80 (+6.51%)
Mar 18, 2026
31w ago
Press Release
NEUTRAL ★ 3/10
$8.98 $8.61▼ −4.12%▼ −2.38%$10.80 (+20.27%)
Showing 9 of 9

US Market Status

Market Closed — Opens Wed (12h)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 22, 2026